Related Experiment Video
Updated: Jun 2, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Indications for growth hormone therapy in children
1Department of Endocrinology, Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK. jeremy.kirk@bch.nhs.uk
Insights
Growth hormone (GH) therapy is used for pediatric conditions like GHD and Turner syndrome to improve growth and body composition. While GH therapy offers choices, cost differences may impact future accessibility for patients.
Area of Science:
- Pediatric Endocrinology
- Biotechnology
- Pharmacology
Background:
- Growth hormone (GH) therapy has been available for over 50 years, with current treatments being biosynthetically produced and administered via daily injection.
- Paediatric GH is approved for six conditions: GHD, TS, SGA, PWS, CRI, and SHOX deficiency, as confirmed by the 2010 NICE review.
Purpose of the Study:
- To review the current landscape of paediatric GH therapy in the UK.
- To discuss the indications, utilization, and future considerations for GH treatment in children.
Main Methods:
- Analysis of UK national audit data on GH therapy.
- Review of licensed indications and treatment outcomes.
Main Results:
- Approximately 4700 children in the UK receive GH therapy, with about 760 new patients annually.
- GH therapy aims to improve growth and body composition, with patient choice of device potentially enhancing adherence.
- A significant price difference among GH products may restrict future patient choice.
Conclusions:
- Paediatric GH therapy remains crucial for specific conditions, with ongoing monitoring of usage and adherence.
- The availability of multiple GH manufacturers and device options presents both opportunities for improved adherence and challenges related to cost and accessibility.
Abstract:
Growth hormone (GH) therapy has now been available for over 5 decades, with all GH now biosynthetically produced, and administered by daily injection. Paediatric GH is currently licensed in six different conditions: growth hormone deficiency (GHD), Turner syndrome (TS), small for gestational age (SGA), Prader-Willi-syndrome (PWS), chronic renal insufficiency (CRI), and short stature due to SHOX deficiency; all of these have been ratified by the most recent (2010) NICE review. Whilst the primary purpose of paediatric GH therapy in most indications is to improve short and long-term growth, in others (eg. PWS) it has a role in improvement of body composition. Recent UK national audits indicate approximately 4700 children receiving GH therapy, with approximately 760 new starts a year, with most prescription still via historical growth centres. There are currently 7 different manufacturers of GH, and while most UK units currently offer free patient choice for GH device, with preliminary evidence indicating that this may improve adherence with therapy, the 30% price difference may limit choice in the future.
Related Concept Videos
Hypoglycemia and Glucagon
Nature and Nurture
Signs of Puberty
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
